Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.
New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.
New research identifies a "strong response endotype" of patients who experience nearly double the sleep apnea improvement from tirzepatide.
This chart highlights key specifications and features among CPAP pillows, including adjustability, dimensions, materials, washability, and price.
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.